In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998

Akira Watanabe, Yutaka Tokue, Hiroshi Takahashi, Toru Kikuchi, Takao Kobayashi, Kazunori Gomi, Shigeru Fujimura, Satoko Yasui, Toshihiro Nukiwa, Satoru Shoji, Yoshihiro Honda

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)


    The in vitro antibacterial activity of biapenem (BIPM), a new carbapenem antibiotic, was compared with those of imipenem (IPM), panipenem (PAPM), meropenem (MEPM), ceftazidime (CAZ) and piperacillin (PIPC) against 280 isolates of 9 respiratory pathogens. The MIC 90 s of biapenem (BIPM) for methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, Moraxella catarrhalis, Pseudomonas aeruginosa, and Haemophilus influenzae were 0.12, 32, 0.25, 0.06, 4 and 8 μg/ml, respectively. In comparison with other antibiotics, the activity of biapenem (BIPM) for P. aeruginosa was as potent as meropenem (MEPM), but for H. influenzae it was slightly less than those of other antibiotics, and for other respiratory pathogens it was as potent as those of other antibiotics. The MIC 90 s of biapenem (BIPM) for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae and Serratia marcescens were 0.06, 1, 1, 0.5 μg/ml, respectively, and which were equal to or somewhat lower than those of other antibiotics. Biapenem (BIPM) showed strong activity against Gram-positive and Gram-negative pathogens, especially P. aeruginosa in general. Based on these results, biapenem (BIPM) is seemed to be highly useful antibiotic for the treatment of respiratory infections with several organism.

    Original languageEnglish
    Pages (from-to)690-694
    Number of pages5
    JournalJapanese Journal of Antibiotics
    Issue number12
    Publication statusPublished - 1999 Dec 1

    ASJC Scopus subject areas

    • Microbiology (medical)
    • Pharmacology (medical)
    • Infectious Diseases

    Fingerprint Dive into the research topics of 'In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998'. Together they form a unique fingerprint.

    Cite this